Study identifier:NIS-ODE-DUM-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A non-interventional study for evaluation of the clinical treatment and patient values and preferences of patients suffering from advanced non-small cell lung cancer (NSCLC) undergoing chemotherapy. With special focus on patients who are in transition from first line to second line treatment
lung cancer
-
No
-
All
120
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.
Location
Location
Heidelberg, Germany
Location
Berlin, Germany
Location
Löwenstein, Germany
Location
Trier, Germany
Location
Hemer, Germany
Location
Essen, Germany
Location
Karlsruhe, Germany
Location
Munchen, Germany
Arms | Assigned Interventions |
---|---|
1 Regular treatment for non-small cell lung cancer (NSCLC) | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.